Show simple item record

Phase 2 study to evaluate the novel mitochondrial PRX3 inhibitor, RSO-021, as an intrapleural monotherapy and in combination with IV paclitaxel in patients with malignant pleural effusion due to mesothelioma or another advanced solid tumor.

dc.contributor.authorDulloo, S
dc.contributor.authorLord, S
dc.contributor.authorFennell, DA
dc.contributor.authorThistlethwaite, F
dc.contributor.authorMaskell, N
dc.contributor.authorPopat, S
dc.contributor.authorBlyth, KG
dc.contributor.authorSzlosarek, PW
dc.contributor.authorAujayeb, A
dc.contributor.authorJaved, SR
dc.contributor.authorHerrero Colomina, J
dc.contributor.authorCunniff, B
dc.contributor.authorDuncan, J
dc.contributor.authorGraham, P
dc.contributor.authorBexon, AS
dc.contributor.authorNaumov, GN
dc.contributor.authorSpicer, JF
dc.date.accessioned2024-06-21T09:32:29Z
dc.date.available2024-06-21T09:32:29Z
dc.date.issued2024-05-29
dc.identifier.citationSean Dulloo et al., Phase 2 study to evaluate the novel mitochondrial PRX3 inhibitor, RSO-021, as an intrapleural monotherapy and in combination with IV paclitaxel in patients with malignant pleural effusion due to mesothelioma or another advanced solid tumor.. JCO 42, TPS8124-TPS8124(2024). DOI:10.1200/JCO.2024.42.16_suppl.TPS8124en_US
dc.identifier.issn0732-183X
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/97601
dc.format.extenttps8124 - tps8124
dc.publisherAmerican Society of Clinical Oncology (ASCO)en_US
dc.relation.ispartofJournal of Clinical Oncology
dc.subjectLungen_US
dc.subjectRare Diseasesen_US
dc.subjectClinical Researchen_US
dc.subjectWomen's Healthen_US
dc.subjectOrphan Drugen_US
dc.subjectClinical Trials and Supportive Activitiesen_US
dc.subjectLung Canceren_US
dc.subjectCanceren_US
dc.subject5 Development of treatments and therapeutic interventionsen_US
dc.subject6.1 Pharmaceuticalsen_US
dc.subject6 Evaluation of treatments and therapeutic interventionsen_US
dc.subject5.1 Pharmaceuticalsen_US
dc.subjectCanceren_US
dc.titlePhase 2 study to evaluate the novel mitochondrial PRX3 inhibitor, RSO-021, as an intrapleural monotherapy and in combination with IV paclitaxel in patients with malignant pleural effusion due to mesothelioma or another advanced solid tumor.en_US
dc.typeArticleen_US
dc.identifier.doi10.1200/jco.2024.42.16_suppl.tps8124
pubs.issue16_supplen_US
pubs.notesNot knownen_US
pubs.volume42en_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record